PaxMedica (NASDAQ: PXMD), a biopharmaceutical company focused on advancing treatments for neurological disorders, is reporting that its phase 2 study research exploring the potential of low-dose suramin intravenous infusions as an autism spectrum disorder (“ASD”) treatment has been published. According … Continue reading →

PaxMedica (NASDAQ: PXMD), a pioneering biopharmaceutical company focused on advancing treatments for neurologic disorders, has set its sights on an exciting potential opportunity. With the engagement of Bourne Partners, a prominent financial services firm specializing in the pharmaceutical and consumer … Continue reading →

PaxMedica (NASDAQ: PXMD), a pioneering biopharmaceutical company focused on advancing treatments for neurologic disorders, is working with leading financial services firm Bourne Partners. Bourne Partners specializes in the pharma, pharma services and consumer health spaces. According to the announcement, the collaboration … Continue reading →

PaxMedica (NASDAQ: PXMD), a pioneering biopharmaceutical company specializing in cutting-edge treatments for neurological disorders, today announced the successful acquisition of certain suramin research assets from Rediscovery Life Sciences (“RLS”). The assets were previously dedicated to the study of suramin’s potential … Continue reading →

PaxMedica (NASDAQ: PXMD), a clinical-stage biopharmaceutical company focusing on the development of novel anti-purinergic drug therapies (“APT”) for the treatment of autism spectrum disorder (“ASD”) and other serious conditions with intractable neurologic symptoms, has released information regarding its 1-for-17 reverse … Continue reading →

PaxMedica (NASDAQ: PXMD), a clinical-stage biopharmaceutical company, announced that its groundbreaking research will be published in the “Annals of General Psychiatry,” an internationally recognized scientific psychiatry publication. The research was reported in a manuscript titled “Randomized clinical trial of low-dose … Continue reading →

PaxMedica (NASDAQ: PXMD), a clinical-stage biopharmaceutical company specializing in innovative treatments for unmet needs in neurodevelopmental disorders, has recently introduced a groundbreaking regulatory strategy that could potentially pave the way for the approval of its lead product candidate, Suramin, in … Continue reading →

PaxMedica (NASDAQ: PXMD), a clinical-stage biopharmaceutical company, today announced the completion of a type-B meeting with the FDA. During the live meeting, the company discussed positive results of the recent data from its PAX-HAT-301 study of suramin in stage one … Continue reading →

PaxMedica (NASDAQ: PXMD), a prominent clinical-stage biopharmaceutical company, was featured in the most recent release of the Bell2Bell podcast series. During the segment, PaxMedia CEO and chair Howard Weisman and PaxMedica corporate communications representative Buzz Woods provided an overview of … Continue reading →

PaxMedica (NASDAQ: PXMD), a prominent clinical-stage biopharmaceutical firm, was featured in the latest episode of the Bell2Bell Podcast, a part of IBN’s sustained effort to provide specialized content distribution via widespread syndication channels. PaxMedica’s CEO and Chairman Howard Weisman and … Continue reading →